Beyond Air Exercises Outstanding Common Warrants For Gross Proceeds Of $3.25M Through Immediate Exercise Of 1.44M Warrants At $2.21/Share; Issues 720K New Warrants At $0.0625 With 5-Year Term

Author: Benzinga Newsdesk | September 08, 2025 03:57pm
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding common warrants (the "Existing Warrants") to purchase up to an aggregate of 1,439,126 shares of the Company's common stock at a reduced exercise price of $2.21 (the closing price of the Company's shares of common stock on September 5, 2025). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.25 million, prior to deducting placement agent fees and estimated offering expenses. Laidlaw & Company (UK) Ltd., is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the Existing Warrants for cash, the Company will issue new unregistered warrants to purchase up to 719,561 shares of common stock ("New Warrants"), at a purchase price of $0.0625 per New Warrant. The New Warrants will have an exercise price of $2.21 per share, will be exercisable immediately and will have a term of five years from the issuance date. 

Posted In: XAIR